Work

Impatto combinato della malattia renale diabetica e della malattia epatica steatosica associata a disfunzione metabolica, definita mediante il Fatty Liver Index, sulla mortalità per tutte le cause e sull’incidenza degli eventi cardiovascolari nel diabete mellito di tipo 2: uno studio osservazionale a lungo termine

Year: 2026
Type: dissertation
Study design: Observational Study
Abstract: Metabolic dysfunction-associated steatotic liver disease (MASLD) and diabetic kidney disease (DKD) are common in people with type 2 diabetes and are associated with increased cardiovascular risk and mortality. In populations with diabetes, MASLD prevalence is estimated at 55–70%, while DKD develops in approximately 30–40% of patients over their lifetime. Their frequent coexistence raises an important clinical question: whether the simultaneous presence of both conditions identifies a worse prognosis than either condition alone. The introductory section of the thesis examines the definition, epidemiology and pathophysiology of MASLD, focusing on insulin resistance, visceral adiposity, dyslipidaemia and inflammation. It also describes progression from steatosis to steatohepatitis and fibrosis, the main non-invasive diagnostic tools, and the relationships between liver disease and cardiovascular and kidney damage. The discussion of treatment approaches covers lifestyle interventions, weight management and the principal drug classes relevant to metabolic and liver disease. This theoretical framework provides the rationale for the research, which considers liver and kidney disease within the broader context of systemic complications of diabetes. The study aims to assess the association of coexisting DKD and MASLD defined using the Fatty Liver Index (FLI-MASLD) with all-cause mortality and major vascular events over long-term follow-up. A distinctive feature is the identification of DKD through reduced kidney function and/or increased albuminuria. This approach includes patients who might be missed by a classification based solely on estimated glomerular filtration rate. The research follows a single-centre, longitudinal observational design. A total of 961 adults with type 2 diabetes were consecutively enrolled between November 2002 and April 2004 and followed for a mean of 13.1 ± 2.8 years, corresponding to 12,546 person-years. Mean baseline age was 59.8 years, and the population included 570 men and 391 women. Vital status was ascertained for all participants as of 31 December 2017. Data on cardiovascular events and other outcomes were available for 947 patients, representing 98.5% of the cohort, through hospital discharge registries. DKD was defined by an estimated glomerular filtration rate below 60 mL/min/1.73 m² and/or a urinary albumin-to-creatinine ratio of at least 30 mg/g. Albuminuria was assessed through repeated measurements, whereas glomerular filtration rate was estimated from baseline serum creatinine. The FLI was calculated using triglycerides, gamma-glutamyltransferase, body mass index and waist circumference. A value of at least 60 was used as a surrogate indicator of steatosis compatible with MASLD. This operational definition identifies FLI-MASLD and does not constitute a diagnosis confirmed by imaging or liver biopsy. Participants were divided into four groups: 325 with neither DKD nor FLI-MASLD (33.8%), 435 with FLI-MASLD alone (45.3%), 39 with DKD alone (4.1%), and 162 with both conditions (16.9%). Overall, FLI-MASLD was present in 62.1% of the cohort and DKD in 20.9%. Groups with FLI-MASLD exhibited greater adiposity and a less favourable metabolic profile, whereas groups with DKD showed greater kidney impairment. The combined phenotype was accompanied by metabolic, inflammatory and vascular abnormalities that could contribute to the observed risk. Prognostic associations were evaluated using Kaplan–Meier curves and Cox regression models, with results expressed as hazard ratios (HRs) and 95% confidence intervals. In addition to unadjusted models and models adjusted for age and sex, multivariable models included cardiovascular risk factors, diabetes duration, glycaemic control, inflammation, insulin sensitivity, baseline treatments and diabetes complications. Fine–Gray analyses were also performed, treating death as a competing event, together with analyses restricted to participants without previous cardiovascular disease and sensitivity analyses using alternative model specifications. During follow-up, 229 deaths were recorded, corresponding to 23.8% of the cohort. Among the 947 participants with event data, there were 273 major cardiovascular events, 181 coronary events, 82 hospitalisations for heart failure, 101 cerebrovascular events, 39 peripheral vascular events and 71 cases of end-stage kidney disease. The proportion of participants who died increased from 16.3% in the group with neither condition to 21.8% with FLI-MASLD alone, 25.6% with DKD alone, and 43.8% in the group with both DKD and FLI-MASLD. Compared with the reference group, coexisting DKD and FLI-MASLD was associated with an adjusted HR for all-cause mortality of 2.66 (95% CI 1.85–3.82). Corresponding HRs were 1.74 (1.24–2.42) for major cardiovascular events, 2.04 (1.34–3.10) for coronary events, 3.86 (1.98–7.52) for hospitalisation for heart failure, and 4.49 (2.16–9.34) for end-stage kidney disease. FLI-MASLD alone also showed significant associations with several outcomes, including mortality, coronary events, heart failure and progression to end-stage kidney disease. Comparisons between the combined phenotype and the isolated conditions revealed differences according to the outcome examined. Mortality was significantly higher than with FLI-MASLD alone (HR 1.85) or DKD alone (HR 2.55). The risk of hospitalisation for heart failure was also higher than with either isolated condition, while the risk of end-stage kidney disease was higher than with FLI-MASLD alone. For major cardiovascular and coronary events, however, adjusted analyses did not identify a significant increase compared with the groups presenting only one condition. The combination of the two diseases therefore did not show a uniform incremental prognostic value across all outcomes. Analyses accounting for competing mortality confirmed the association of the combined phenotype with major cardiovascular events, coronary events, heart failure hospitalisations and end-stage kidney disease compared with the absence of both conditions. The main findings remained consistent after excluding participants with cardiovascular disease at baseline. Sensitivity analyses also supported the stability of the associations despite the partial overlap between variables used to calculate the FLI and estimate insulin sensitivity. Subgroup analyses were exploratory and require confirmation. Strengths include the long observation period, complete ascertainment of vital status and detailed clinical characterisation, including repeated assessment of albuminuria. Limitations include the single-centre design, the small group with DKD alone, the absence of imaging confirmation of steatosis, and the lack of consideration of changes in clinical characteristics and treatments during follow-up. Recruitment in 2002–2004 and the exclusively European composition of the cohort also limit generalisability to contemporary patients and other populations. The observational design and potential residual confounding prevent the associations from being interpreted as evidence of causality. The study indicates that coexisting DKD and FLI-MASLD identifies a phenotype with a particularly unfavourable prognosis in type 2 diabetes, especially for mortality, hospitalisation for heart failure and end-stage kidney disease. Joint assessment of kidney function, albuminuria and liver health could contribute to a more comprehensive evaluation of long-term risk. These findings support an integrated clinical approach and require validation in contemporary multicentre cohorts with more detailed characterisation of liver disease and treatment exposure over time.
Institution: University of Pisa
Language: Italian
Subfield: Hepatology
Field: Medicine
Open Access status: green
OpenAlex ID: W7225843216
Cites: 97
Cited by:
Related to: 10